Advertisement

Immunotoxins in Cancer Therapy

  • F. K. Jansen
  • C. Blazy
  • H. E. Blythman
  • B. Bourrie
  • P. Carayon
  • P. Casellas
  • J. M. Derocq
  • D. Dussossoy
  • P. Gros
  • O. Gros
  • G. Laurent
  • G. Richer
  • H. Vidal
Part of the NATO ASI Series book series (NSSA, volume 155)

Abstract

Immunotoxins (ITs) have now been studied for more than 10 years. They were found to be active under in vitro conditions and were utilized with success for the ex vivo pretreatment of human bone marrow transplantations. The new challenge today is to render them efficient under in vivo conditions. ITs assembled with whole toxins such as ricin, diphtheria toxin or Pseudomonas exotoxin show considerable nonspecific cytotoxicity due to the recognition of receptors on almost every cell type by the B-chain part of the toxins and are therefore not adequate for in vivo therapy.

Keywords

Human Serum Albumin Leucine Incorporation Photoaffinity Label Pseudomonas Exotoxin Actuarial Disease Free Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Casellas, P., Bourrié, B. J. P., Gros, P., and Jansen, F. K., 1984, Kinetics of cytotoxicity induced by immunotoxins: Enhancement by lysosomotropic amines and carboxylic ionophores, J.of Biol.Chem., 259:9359.Google Scholar
  2. Casellas, P., and Jansen, F. K., 1987, Enhancement of A-chain immunotoxins by pharmacological agents, in: “Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer,” C. W. Vogel, ed., Oxford University Press, New York, 97–115.Google Scholar
  3. Eccles, S. A., Mcintosh, D. P., Purives, H. P., Cumber, A. J., Parnell, G. D., Forrester, J. A., Styles, J. M. and Kean, C. J., 1987, An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B-chain, Cancer Immunol.Immunother, 24:37.PubMedCrossRefGoogle Scholar
  4. Houston, R. R., 1983, Inactivation of ricin using 4-azidophenyl-B-D-galactopyranoside and 4-diazophenyl-B-D-galactopyranoside, J.Biol.Chem., 258:7208.PubMedGoogle Scholar
  5. Jansen, F. K., Blythman, H. E., Carrière, D., Casellas, P., Gros, O., Laurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H., and Voisin, G.A., 1982, Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity, Immunol.Rev., 62:185.PubMedCrossRefGoogle Scholar
  6. Laurent, G. D., Maraninchi, D., Gluckman, E., Vernant, J. P., Derocq, J. M., Gaspard, M., Rio, B., Michalet, M., Reiffers, J., Dreyfus, F., Casellas, P., Bouloux, C., Schneider, P., Blythman, H. E., and Jansen, F. K., 1988, Donor bone-marrow treatment with Fab T101 fragment-ricin A-chain immunotoxins prevents graft versus host desease (submitted).Google Scholar
  7. Macintosh, D. P., Edwards, D. C., Cumber, A. J., Parnell, G. D., Dean, C. J., Ross, W. C. J., and Forrester, A., 1983, Ricin B-chain converts a non cytotoxic antibody-ricin A-chain conjugate into a potent and specific cytotoxic agent, F.E.B.s Lett., 164:17.CrossRefGoogle Scholar
  8. Montfort, W., Villafranca, J. E., Monzingo, A. F., Ernst, S. R, Katzin, B., Rutenber, E., Xuong, N. H., Hamlin, R., and Robertus, J. D., 1987, The three-dimensional structure of ricin at 2.8 A*, J.Biol.Chem., 262:5398.PubMedGoogle Scholar
  9. Raso, V., and Lawrence, J., 1984, Carboxylic ionophores enhance the cytotoxic potency of ligand and antibody delivered Ricin A-chain, J.Exp.Med., 160:1234.PubMedCrossRefGoogle Scholar
  10. Thorpe, P. E., Ross, W. C. J., Brown, A. N. F., Myers, C. D., Cumber, A. J., Foxwell, B. M. J., and Forrester, J. T., 1984, Blockade of the galactose-binding sites of ricin by its linkage to antibody, Eur.J.Biochem., 140:63.PubMedCrossRefGoogle Scholar
  11. Vallera, D. A., Quinones, R. R., Azemove, S. M., and Soderling, C. C. B., 1984, Monoclonal antibody-toxin conjugates reactive against human T-lymphocytes, Transplantation, 37:387.PubMedCrossRefGoogle Scholar
  12. Vitetta, E. S., Fulton, R. N., and Uhr, J. W., 1984, Cytotoxicity of a cell-reactive immunotoxin containing ricin A-chain is potentiated by an anti-immunotoxin containing ricin B-chain, J.Exp.Med., 160:341.PubMedCrossRefGoogle Scholar
  13. Vitetta, E. S., 1986, Immunotoxins prepared with chemically-modified ricin B chains that lack lectin activity can potentiate the killing of target cells by ricin A-chain-containing immunotoxins, J.Immunol., 136:1880.PubMedGoogle Scholar
  14. Youle, R. J., and Neville, D. M., 1982, Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids -Role of the ricin B subunit demonstrated by reconstitution, J.Biol.Chem., 257:1598.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • F. K. Jansen
    • 1
  • C. Blazy
    • 1
  • H. E. Blythman
    • 1
  • B. Bourrie
    • 1
  • P. Carayon
    • 1
  • P. Casellas
    • 1
  • J. M. Derocq
    • 1
  • D. Dussossoy
    • 1
  • P. Gros
    • 1
  • O. Gros
    • 1
  • G. Laurent
    • 1
  • G. Richer
    • 1
  • H. Vidal
    • 1
  1. 1.Sanofi RechercheCentre de MontpellierMontpellierFrance

Personalised recommendations